- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Ryan Haumschild, PharmD, Advises Practices, Health Systems to Prep for Interchangeable Biosimilars
Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, gives an overview of what practices and health systems need to prepare for as more interchangeable biosimilars enter the US market.
Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, gives an overview of what practices and health systems need to prepare for as more interchangeable biosimilars enter the US market.
Transcript
How do you think interchangeability will play into future decisions regarding formulary placement of biosimilars?
Interchangeability is a hot topic. We already have our first [interchangeable] insulin [biosimilar]. I saw it first it at The Center for Biosimilars® when that news came out, and I think we're gonna see it in a lot more areas and so that gives pharmacy a lot more of that responsibility to change out the products as needed. I will say we've worked already to create a formulary P&T [pharmacy and thearapeutics] approval where we can exchange biosimilars as needed, based on payer preferences, based on organizational preferences, and that's worked out really well. But I think as you see interchangeability, you might see a little bit of leveraging those products that have better interchangeability come up forward a little more, because we can have better control, ultimately, of what we're dispensing to patients. And again, when you have better control and you have the potential to interchange, you just have to make sure you're doing it on label. So, it's little complex. I think we figured it out from a from a P&T perspective, but I do think it'll start to play more of a role as we preference and try to splice out the differences between therapies.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
The Top 5 Most-Read Conference Articles of 2024
December 26th 2024The top 5 biosimilar conference articles in 2024 highlight significant progress in the biosimilar landscape, including strategies for market sustainability, safety of switching to biosimilars, and substantial savings through high biosimilar adoption, while also addressing ongoing challenges.
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
